Oral Typhoid Vaccines

Global Oral Typhoid Vaccines Market to Reach US$248.7 Million by 2030

The global market for Oral Typhoid Vaccines estimated at US$138.3 Million in the year 2024, is expected to reach US$248.7 Million by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$142.6 Million by the end of the analysis period. Growth in the Retail Pharmacies segment is estimated at 11.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$37.7 Million While China is Forecast to Grow at 13.8% CAGR

The Oral Typhoid Vaccines market in the U.S. is estimated at US$37.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$50.5 Million by the year 2030 trailing a CAGR of 13.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.5% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Global Oral Typhoid Vaccines Market – Key Trends & Drivers Summarized

Can Oral Vaccination Strategies Revolutionize Typhoid Control in Endemic Regions?

Oral typhoid vaccines, primarily based on live attenuated strains like Salmonella Typhi Ty21a, are playing a transformative role in the global strategy to combat enteric fever, particularly in low-resource, high-burden regions of Asia and sub-Saharan Africa. Unlike injectable Vi polysaccharide or conjugate vaccines, oral formulations offer the advantages of needle-free administration, mucosal immunity stimulation, and ease of deployment in mass immunization campaigns. As global public health efforts intensify to curb typhoid morbidity and mortality, oral vaccines are gaining renewed attention for their scalability and acceptability, especially in children and adolescents.

The World Health Organization (WHO) has endorsed oral vaccines for travel-related and endemic typhoid control, recognizing their potential to complement parenteral options in diverse population segments. Moreover, the increasing prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) typhoid strains has elevated the importance of preventive vaccination. Oral typhoid vaccines serve as a critical first line of defense in regions where antibiotic treatment options are becoming increasingly limited or ineffective.

Why Are Vaccine Compliance and Cold Chain Advantages Driving Oral Adoption?

In contrast to injectable vaccines, oral typhoid vaccines such as Vivotif® eliminate the need for trained healthcare workers for administration and reduce the risk of needle-stick injuries or infections. This makes them particularly effective in rural and peri-urban areas with limited medical infrastructure. Oral vaccines also promote higher compliance, especially in school-based vaccination programs or travel clinics, where multi-dose schedules can be administered with fewer logistical barriers.

Moreover, oral vaccines typically have better cold chain resilience compared to their parenteral counterparts. Some formulations demonstrate stability across a wider temperature range, simplifying storage and transportation during field campaigns. These features are critical for outreach in remote or disaster-prone regions where electricity and refrigeration are unreliable. Such operational flexibility is positioning oral typhoid vaccines as an integral part of emergency response toolkits and humanitarian health interventions.

How Are Policy Shifts and Public Health Programs Expanding Vaccine Uptake?

International donor agencies and national immunization programs are increasingly recognizing the role of oral typhoid vaccines in integrated disease control. Public health partnerships supported by Gavi, the Vaccine Alliance, and UNICEF are promoting vaccine introduction in endemic regions with a dual approach: deploying injectable conjugate vaccines for infants and oral vaccines for older age groups or travelers. Countries such as India, Bangladesh, Nepal, and Kenya are incorporating oral vaccines into travel advisories, military health protocols, and refugee health programs.

Post-vaccination surveillance data is strengthening the case for broader oral vaccine inclusion in routine immunization. Studies show that Ty21a-based vaccines not only reduce typhoid incidence but also confer moderate cross-protection against Salmonella Paratyphi B, further enhancing their epidemiological value. Pharmaceutical manufacturers are responding by improving shelf stability, extending dosage intervals, and developing reformulations targeted at pediatric use and wider strain coverage.

What’s Driving the Rising Global Demand for Oral Typhoid Vaccines?

The growth in the oral typhoid vaccines market is driven by rising awareness of typhoid burden, global travel resumption post-pandemic, and strategic investments in disease prevention infrastructure. A key growth driver is the increasing recognition of oral vaccines as an efficient, cost-effective solution in regions where healthcare access is fragmented. Global travel advisories and university immunization programs also continue to support demand for oral vaccines among travelers and expatriates to typhoid-endemic zones.

In addition, urbanization, poor sanitation, and climate-linked water contamination are sustaining typhoid transmission risks in densely populated regions—necessitating preventive public health measures. Regulatory approvals and WHO prequalification of key oral vaccines are enabling procurement through international supply chains, further expanding market accessibility. As typhoid re-emerges as a public health priority amid rising antimicrobial resistance, oral vaccines will continue to gain traction as both a standalone and complementary solution in global immunization strategies.

With ongoing innovations in vaccine delivery, expanded policy endorsement, and robust supply chain integration, the oral typhoid vaccines market is positioned for sustained growth. These vaccines will remain vital tools for achieving typhoid control and elimination goals across high-risk geographies and mobile populations.

SCOPE OF STUDY:

The report analyzes the Oral Typhoid Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Bavarian Nordic
• Bharat Biotech
• Bio Farma
• Biological E. Limited
• Crucell (a Johnson & Johnson company)
• Emergent BioSolutions
• GlaxoSmithKline plc (GSK)
• Haffkine Bio-Pharmaceutical Corporation Ltd.
• Indian Immunologicals Ltd.
• Merck & Co., Inc.
• Panacea Biotec Ltd.
• PaxVax (now part of Emergent BioSolutions)
• PT Bio Farma
• Sanofi Pasteur
• Serum Institute of India
• Shanta Biotechnics Ltd.
• SK Bioscience
• Takeda Pharmaceutical Company
• Valneva SE
• Zydus Cadila

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.